Phase II Trial of INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Summary
The purpose of this phase II study is to evaluate the clinical activity of INCMGA00012 in patients with unresectable or metastatic adenosquamous pancreatic or ampullary cancer.
General Information
NCT#: NCT04116073
Study ID: J19106
Trial Phase: Phase II
Trial Sponsor: Incyte Corporation, Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Retifanlimab